{"name":"Tempest Therapeutics","slug":"tempest","ticker":"TPST","exchange":"NASDAQ","domain":"tempesttx.com","description":"Tempest Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer. The company's lead product candidate, TPST-1122, is a monoclonal antibody targeting the CD137 receptor, which is involved in the activation and proliferation of T cells. TPST-1122 has shown promising results in clinical trials, and the company is exploring its potential in various cancer indications. With a strong pipeline and a focus on oncology, Tempest Therapeutics is well-positioned to make a significant impact in the industry.","hq":"South San Francisco, CA, United States","founded":0,"employees":"","ceo":"Stephen Brady","sector":"Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$85M","metrics":{"revenue":295000,"revenueGrowth":-54.8,"grossMargin":0,"rdSpend":18337000,"netIncome":-41843000,"cash":41488000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"TPST-1122 patent cliff ($0.00 at risk)","drug":"TPST-1122","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Tempest Therapeutics Announces FDA Clearance of IND for TPST-1122","summary":"The FDA has cleared the Investigational New Drug (IND) application for TPST-1122, allowing the company to proceed with clinical trials.","drugName":"TPST-1122","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Tempest Therapeutics Reports Third Quarter 2023 Financial Results","summary":"The company reported a net loss of $13.4 million for the third quarter of 2023, with research and development expenses increasing to $10.4 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxOYzFoaG1UQzRjdnY4UUM4RVhMN2RDc1RlU2VYUFRFVWlYbC16ZTFaUnE3dnVzY2xNVmYzWHRUTUFNQkFMcnlBTy1TSFBnQ05BNVM0d3BGWHRaTEhJZjBKWS1GVjZBbmgwZ3dfNU9ubDlLOHowVjVCZl9DNXFXUThKTmpfQlBMVEFCMkdFdGZsZi1obVdDU2xDNlBzbnpKcGFNbHVjMHdXa1RfNVJoa2p5bWxFOEpjWHNEVzZxbFpNb19id1E5X2dRbGl5OFZxY1pKMU9Zcm9OWEdYbmRSdTVVdTVBWHRwT05FeFllNjZjNk5LUQ?oc=5","date":"2026-02-11","type":"deal","source":"GlobeNewswire","summary":"Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets - GlobeNewswire","headline":"Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets","sentiment":"neutral"},{"date":"2026-02-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNZWNaTldGeEVZV0hMSU5qYXI1VEVJN0xReTAyNzRzdzZWOWtITjR3YmpsOG1rTlBsX0J5ZjNHM3FjX3gtSmlJTWJGYnlsUEN2dzhOXy1oN3N1THFHVS1vbi1tRVZncWo5dGVSZDZjbnJ1bnN6ZElvMUVSRGxtX1RiVFpjc0c0eWpfUVRWME55MDN5clJpRXdvMlFPM0NEanRSclZxalFzV0hFa25tcjZrUHJlTnFGSmJXRlJtRmp3?oc=5","date":"2025-11-19","type":"deal","source":"Stock Titan","summary":"Tempest (Nasdaq: TPST) to buy CD19/BCMA Dual-CAR T assets, runway to mid 2027 - Stock Titan","headline":"Tempest (Nasdaq: TPST) to buy CD19/BCMA Dual-CAR T assets, runway to mid 2027","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE0wWmFVcWplRWJpSHhNRUVydlhkYV9QRThYOUZNcU9lejJUVFlTRjlualBVOXprMGhWRWxDcHRIUFhQbWk2aXdvandhZDVmOTZjcXVUSUY5bUQycDJuckdvY21n?oc=5","date":"2025-04-22","type":"pipeline","source":"The Pharma Letter","summary":"Tempest Therapeutics - The Pharma Letter","headline":"Tempest Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNcjlkVGpBSTlLdFdsQnVneVJRZFNvZlVzbjlSSkJlNGxzOUhvd05kdlZWUHdDeHM0QXN0ZmNIdkN6LTB3YzQ4MjdKZTdWTGZPcFZILWtKWkcxYmJ1Vk5wY3Fuc2pGZHJ1THZOYlEwMWNZWWZEVzZZQWFianVFT0RjSjVMRFFVXzZXNFpHTzBRSjB2UlV0UElFY0JXMzVmajFCZF9xMWlwVWdLMGlFbHdKdlQ4YWlxWjNV?oc=5","date":"2025-04-10","type":"trial","source":"Pharmaceutical Technology","summary":"Tempest hits funding block for Phase III liver cancer drug-in-waiting - Pharmaceutical Technology","headline":"Tempest hits funding block for Phase III liver cancer drug-in-waiting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOZGhTU0U1bjBHQW4yTFJNVEVyWnZLcEloajBxMmpabjhzQ0dsYjVsUW84WWZ0aUM5R3BYdzZQbnkyUkxGby15YW9CRXlITVZvTlJ4NkdrMXJtdS1vNjVrdDc0VGkwMFJ0clFJcE9MOVd5VDBrSlBKYk1GaTc1ZW9LTnJBRWh2R2RGZHhrZDN3Vm1KaVdnNjR3UUVmRjJncUMyUkdIclZONnBPVnNabkRiekFLaw?oc=5","date":"2025-04-07","type":"pipeline","source":"Investing.com","summary":"Tempest Therapeutics announces 1-for-13 reverse stock split - Investing.com","headline":"Tempest Therapeutics announces 1-for-13 reverse stock split","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPeUxWNTNuMWRFWlV2UVFyRWhYWHpKQ3J5ZzZVSDZ5OXAyTkVFZlRBcjQyd3BmWmFiMWtnVHJnVFVBYkMweXh2MzRTazgzNlJadlF1ME1JeHVMQ2pFUkp2R1J5bWhuSW84RGVCTUhaazNYVVhmNnF6ZlZiU1ZQWkl5Z2c4Nk1fbE9sa3dVNERuV2VsblJ2R1hBbVdjeTJaMnoxeWlCdUtpcnBWVG1V?oc=5","date":"2024-04-17","type":"pipeline","source":"Seeking Alpha","summary":"Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch (NASDAQ:TPST) - Seeking Alpha","headline":"Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch (NASDAQ:TPST)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE0zNmVlYlRxN29pWkZUVThYNXllLU5zZXZZQi1hVzc4QldCakcwUDRwdml3NUl0b3lhQXlFSjFPLVcxYTZOTkNzLUkxWU0tR2Vs?oc=5","date":"2023-10-12","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPTnl2eVFPNjQ2clNPUVJ2OTFxdkRuRVVoN0FWSUtKWkVsR0h1amg4dEtaWnR3MDNJYllNTkRtdXBIRHJqb19ITTM1bzBjbmsxM1czVG1tMXIwWGMxWkpYV2Z1VDhmQ256di1WdnJ2M3VudktrTDdLeXJldzlzdHczaE9RRlA?oc=5","date":"2023-10-12","type":"pipeline","source":"InvestorPlace","summary":"Why Is Phio Pharma (PHIO) Stock Down 35% Today? - InvestorPlace","headline":"Why Is Phio Pharma (PHIO) Stock Down 35% Today?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9GcGVhSnJsUU9zT2F0dE1PcVJTYlZxUi1PZHpxc3FWRnpGT0NRSTRhbFNSc2d2NTZMR1dtRjNWLXNNMzU4ZDFVSWNmZnNKc19GR19IZE9IT3JHRGJu?oc=5","date":"2021-07-11","type":"pipeline","source":"TradingView","summary":"TPST Stock Price and Chart — NASDAQ:TPST - TradingView","headline":"TPST Stock Price and Chart — NASDAQ:TPST","sentiment":"neutral"}],"patents":[{"drugName":"TPST-1122","drugSlug":"cd137-receptor-antagonist","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","AstraZeneca"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":295000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":295000,"period":"2017-12-31"},{"value":653000,"period":"2016-12-31"},{"value":653000,"period":"2016-12-31"},{"value":277000,"period":"2015-12-31"},{"value":277000,"period":"2015-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":18337000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-41843000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":41488000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}